Drug Type Monoclonal antibody |
Synonyms CAN 10, CAN-10 |
Target |
Action inhibitors |
Mechanism IL1RAP inhibitors(Interleukin-1 receptor accessory protein inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization |
Drug Highest PhasePhase 1 |
First Approval Date- |
RegulationOrphan Drug (United States) |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Plaque psoriasis | Phase 1 | Germany | 21 Aug 2023 | |
Hidradenitis Suppurativa | Phase 1 | Sweden | - | |
Scleroderma, Systemic | Phase 1 | Sweden | - | |
Myocarditis | Clinical | Sweden | 21 Sep 2023 | |
Atherosclerosis | Preclinical | United States | 02 Apr 2024 |
NCT06143371 (Biospace) Manual | Phase 1 | - | riqqhzqzyj(idskvaccrh) = No safety concerns have been observed and the eighth dose group is about to start in accordance with the protocol. gierxcmykh (iqdphrlxcl ) | Positive | 14 Jun 2024 | ||
NCT06143371 (Biospace) Manual | Phase 1 | - | xojrnlzdep(cbnptcyznv) = the first clinical data set shows good safety hebovbovfk (nxgafmuelk ) View more | Positive | 14 Mar 2024 |